Abstract
Background
While the overall incidence of gastric cancer has declined in the United States of America, the incidence of proximal gastric cancers has increased. The purpose of this analysis was to highlight key differences between proximal and distal gastric cancer as they relate to presentation and treatment.
Methods
Data on 6,099 patients diagnosed with gastric adenocarcinoma were collected as a patient care evaluation under the auspices of the American College of Surgeons Commission on Cancer. The chi-square (χ 2) test was used for comparisons of proportions across levels of categorical variables by site.
Results
The proximal cancer group included 1,924 patients (87% cardia, 13% fundus) and the distal cancer group included 1,311 patients (85% antrum, 15% pylorus). Proportionately, proximal cancer cases were male (P < 0.01), younger (P < 0.01), and White (P < 0.01); whereas, distal gastric cancer cases were Black (P < 0.01), Hispanic (P < 0.01), and Asian (P = 0.01). Surgery alone (without adjuvant chemotherapy or radiation) was utilized more frequently in distal disease (39.5%) compared to proximal disease (25.7%) (P < 0.01). Preoperative adjuvant therapy was utilized more frequently in proximal disease (41.7%) compared to distal disease (2.1%) (P < 0.01).
Conclusions
The populations that developed proximal verses distal gastric cancer differed with respect to sex, age, and racial background. Cancer-directed treatments also differed based upon tumor location. Understanding these differences may someday enable us to identify important high-risk populations, prevention strategies, and ultimately best treatment strategies. Long-term survival differences will be explored when follow-up data become available.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Jemal A, Siegel R, Ward E, et al. Cancer Statistics 2006. CA Cancer J Clin 2006; 56:106–30
Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55:74–108
Brown LM, Devesa SS. Epidemiologic trends in esophageal and gastric cancer in the United States. Surg Oncol Clin North Am 2002; 11:235–56
Devesa SS, Blot WJ, Fraumeni JF Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998; 83:2049–53
Jessup JM, Winchester DP, Menck HR, et al. National Cancer Data Base annual review of patient care. American Cancer Society, Atlanta, GA 1995:1–11
Jessup JM, Menck HR, Winchester DP, et al. The National Cancer Data Base report on patterns of hospital reporting. Cancer 1996; 78:1829–37
North American Association of Central Cancer Registries (2002) Standards for Cancer Registries, Vol. II. In: Hultstrom D, (ed). Version 10. Chap. IX. Required Status Table. Springfield, IL: NAACCR, pp. 107–118
Commission on Cancer (1998) Standards of the Commission on Cancer, Vol. II: Registry Operations and Data Standards. Chicago, IL: American College of Surgeons
Shaffer JP. Multiple hypothesis testing. Ann Rev Psych 1995; 46:561–84
Hoerr SO. Carcinoma of the Stomach. In: Nyhus LM, Wastell C, eds. Surgery of the stomach and duodenum, 3rd ed. Boston: Little, Brown and Company. 1977; 649–72
Locke GR 3rd, Talley NJ, Carpenter HA, et al. Changes in the site- and histology-specific incidence of gastric cancer during a 50-year period. Gastroenterology 1995; 109:1750–6
Powell J, McConkey CC. Increasing incidence of adenocarcinoma of the gastric cardia and adjacent sites. Br J Cancer 1990; 62:440–3
Bonenkamp JJ, Hermans J, Sasako M, et al. Dutch Gastric Cancer Group. Extended lymph-node dissection for gastric cancer. N Engl J Med 1999; 340:908–14
Cuschieri A, Weeden S, Fielding J, et al. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Br J Cancer 1999; 79:1522–30
Hundahl SA. Surgical quality control in gastric cancer trials. Surg Oncol Clin North Am 2002; 11:445–58
Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001; 345:725–30
Gastric Cancer Clinical Practice Guidelines in Oncology. NCCN practice guidelines. National Comprehensive Cancer Network 2003; 1:28–39
Greene FL, Page DL Fleming ID, et al. (eds) American Joint Committee on Cancer Staging Manual. 6th ed. Philadelphia: Springer, 2002
Wanebo HJ, Kennedy BJ, Chmiel J, et al. Cancer of the stomach. A patient care study by the American College of Surgeons. Ann Surg 1993; 218:583–92
Macdonald J, Smalley S, Benedetti J, et al. Postoperative combined radiation and chemotherapy improves disease-free survival (DFS) and overall survival (OS) in resected adenocarcinoma of the stomach and GE junction. Results of Intergroup Study INT-0116 (SWOG 9008). Proc Am Soc Clin Oncol 19: 2000 (abstr 1)
Walsh TN, Noonan N, Hollywood D, et al. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 1996; 335:462–7
Standards of the Commission on Cancer, Vol II. Registry Operations and Data Standards (ROADS), 1998
Siewert JR, Feith M, Stein HJ. Biologic and clinical variations of adenocarcinoma at the esophago-gastric junction: relevance of a topographic-anatomic subclassification. J Surg Oncol 2005; 90:139–46
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Wilkinson, N.W., Howe, J., Gay, G. et al. Differences in the Pattern of Presentation and Treatment of Proximal and Distal Gastric Cancer: Results of the 2001 Gastric Patient Care Evaluation. Ann Surg Oncol 15, 1644–1650 (2008). https://doi.org/10.1245/s10434-008-9877-2
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-008-9877-2